Diclofenac and dexamethasone modulate the effect of cannabidiol on the rat colon motility <i>ex vivo</i>

Abstract Introduction Due to the growing interest in use of cannabinoids supportive therapies, they are increasingly used together with anti-inflammatory drugs. Cannabinoids inhibit gastrointestinal motility, while steroidal and nonsteroidal drugs influence motility other ways. The aim research was study interactions between cannabidiol (CBD) these two classes context motility. Dexamethasone (DEX) selected as a drug diclofenac (DCF) counterpart. Material Methods experiments were performed on isolated rat colon strips isometric conditions. contractile response acetylcholine (ACh) (1 μM) measured no substance applied control value after application CBD (80 μM), DEX (100 DCF or combination substances. Results Cannabidiol strongly inhibited intestinal mediated by ACh application, it non-significantly, intensified it. When co-administered DEX, non-significantly relative ACh-only control. Co-administration more than when substances administered separately. Conclusion Inhibition is likely due synergistic effect endogenous cannabinoids. lessened inhibitory CBD, because diminished availability arachidonic acid necessary for cannabinoid synthesis. However, may increase synthesis, greater caused blocking cyclooxygenation pathway.